Investor Presentation Full Year 2021
49
Investor presentation Full year 2021
Novo NordiskⓇ
The global GLP-1 market penetration varies across regions with
Novo Nordisk having a best-in-class marketed portfolio
80%
60%
40%
20%
GLP-1 market growth and Novo Nordisk market share
GLP-1 value and patient share¹ of the total diabetes market
30%
60%
27%
53%
20%
38%
31%
18%
The
32%
9%
10%
7%
6%
3%
3%
1%
0%
0%
World
Nov
Nov
North
EMEA
Region
2018
2021
America
China
NN market share
NN share of growth
■GLP-1 value share of total diabetes
Market growth
NN growth
■GLP-1 patient share of total diabetes
1%
ROW
1Patient share based on data for the USA, the UK, Germany and France only.
Note: EMEA: Europe, Middle East and Africa; RoW: Rest of World
Source: IQVIA MAT value (spot rate), Nov 2021View entire presentation